BIIB
BIOGEN INC.
Nasdaq: BIIB · Cambridge, MA · Healthcare
$220.83-3.68 (-1.64%)Closed
Market Cap$32.42B
Cash$2.91Bmost recent
Runwayprofitable
P/E (TTM)25.1EPS $8.79
52-Wk Range$135.67 – $224.51
Avg Volume1.4M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$220.83+9.4%
Pipeline

Drug candidates sponsored by BIOGEN · ClinicalTrials.gov

74 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Methylprednisolone
Immune Reconstitution Inflammatory Syndrome+1 more
Terminated
2012-02past
1
Phase 4Interferon beta-1a
Relapsing Remitting Multiple Sclerosis+1 more
Completed
2014-09past
3
Phase 4Natalizumab
Multiple Sclerosis+5 more
Completed
2015-07-28past
7
Phase 4Unnamed
Relapsing-Remitting Multiple Sclerosis
Completed
2018-01-27past
1
Phase 4dimethyl fumarate
Multiple Sclerosis, Relapsing-Remitting+1 more
Completed
2022-09-14past
4
Phase 3Placebo
Relapsing-Remitting Multiple Sclerosis+1 more
Completed
2015-06-16past
1
Phase 3fampridine
Multiple Sclerosis+1 more
Completed
2016-02past
2
Phase 3SAGE-217
Major Depressive Disorder+1 more
Completed
2021-03-26past
2
Phase 3Aducanumab
Alzheimer's Disease+1 more
Completed
2024-07-22past
4
Phase 3BIIB074
Trigeminal Neuralgia+1 more
Terminated
2025-08-18past
2
Phase 3BIIB111
Choroideremia+1 more
Completed
2026-06-22past
2
Phase 3Felzartamab
Antibody-mediated Rejection
Active, not recruiting
2026-12-01
1
Phase 3BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting
Active, not recruiting
2027-05-20
1
Phase 3Tofersen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation+1 more
Active, not recruiting
2027-08-07
2
Phase 3nusinersen
Spinal Muscular Atrophy+1 more
Active, not recruiting
2027-09-24
5
Phase 3BIIB059 (litifilimab)
Subacute Cutaneous Lupus Erythematosus+1 more
Enrolling
2029-06-26
1
Phase 3Salanersen
Muscular Atrophy, Spinal
Recruiting
2029-07-27
1
Phase 3Zevalin (ibritumomab tiuxetan)
Non-Hodgkin's Lymphoma
Terminated—1
Phase 3Alefacept
Chronic Plaque Psoriasis
Completed—1
Phase 1IDEC-114
Non-Hodgkin's Lymphoma
Completed
2004-03past
1
Phase 2Baminercept alfa 1
Rheumatoid Arthritis
Completed
2008-10past
1
Phase 2BG9924
Rheumatoid Arthritis
Terminated
2008-10past
1
Phase 2BG9418 (Interferon beta-1a)
Active Ulcerative Colitis
Completed
2010-03past
1
Phase 2Bardoxolone Methyl (RTA 402)
Chronic Kidney Disease+2 more
Completed
2010-05-31past
1
Phase 1mefloquine
Progressive Multifocal Leukoencephalopathy
Terminated
2010-11past
1
Phase 2natalizumab IV
Relapsing-Remitting Multiple Sclerosis
Completed
2014-04past
1
Phase 2BIIB019 (Daclizumab)
Relapsing-Remitting Multiple Sclerosis
Completed
2016-08-25past
1
Phase 2BG00011
Idiopathic Pulmonary Fibrosis
Terminated
2019-11-14past
1
Phase 2Bardoxolone methyl oral capsule
Chronic Kidney Diseases
Completed
2021-10-20past
1
Phase 2MOR202
Glomerulonephritis+2 more
Completed
2023-12-14past
1
Phase 1BIIB105
Amyotrophic Lateral Sclerosis
Terminated
2024-08-13past
1
Phase 1IDEC-152
Chronic Lymphocytic Leukemia
Completed
2004-04past
1
Phase 1RTA 744
Leptomeningeal Carcinomatosis
Terminated
2008-12-01past
1
Phase 1BG00012
Relapsing Remitting Multiple Sclerosis
Completed
2009-10-31past
1
Phase 1BIIB021 and Food
Advanced Solid Tumors
Completed
2010-08past
1
Phase 1Galiximab
Lymphoma, Non-Hodgkin's
Terminated
2010-11past
1
Phase 1Avonex
Healthy
Completed
2011-10past
1
Phase 1Interferon beta-1a (current approved manufacturing process invloving FBS)
Multiple Sclerosis
Completed
2012-04past
1
Phase 1BG00010 (Neublastin)
Sciatica
Completed
2012-09past
1
Phase 1BIIB023
Healthy
Completed
2014-01past
1
Phase 1BIIB019 subcutaneous injection
Healthy
Completed
2014-03past
1
Phase 1RTA 408 Lotion 0.5%, 1%, 3%
Healthy
Completed
2014-04-01past
1
Phase 1CNV1014802
Healthy
Completed
2016-08-16past
1
Phase 1Bardoxolone methyl capsules 10 mg
Healthy Volunteers
Completed
2017-11-13past
1
Phase 1BIIB054
Parkinson's Disease+1 more
Completed
2017-11-20past
1
Phase 1SAGE-217 high dose
Healthy
Completed
2017-12-04past
1
Phase 1[14C]-Omaveloxolone
Healthy Male Subjects
Completed
2019-05-31past
1
Phase 1BIIB104
Healthy Volunteers
Completed
2019-12-27past
1
Phase 1BIIB076
Alzheimer's Disease+1 more
Completed
2020-03-03past
1
Phase 1DNL151
Parkinson's Disease
Completed
2020-12-02past
1
Phase 1BIIB100
Amyotrophic Lateral Sclerosis
Completed
2021-06-21past
1
Phase 1BIIB104 Reference Formulation
Healthy Volunteers
Completed
2022-01-31past
1
Phase 1BIIB091
Healthy Volunteers
Completed
2022-09-07past
1
Phase 1BIIB113
Healthy Volunteer
Completed
2023-07-10past
1
Phase 1BIIB132
Spinocerebellar Ataxia Type 3
Terminated
2023-07-25past
1
Phase 1BIIB107
Healthy Volunteers
Completed
2024-03-05past
1
Phase 1BIIB122
Healthy Volunteer
Completed
2024-06-18past
1
Phase 1omaveloxolone
Metastatic or Incurable Non-small Cell Lung Cancer+4 more
Recruiting
2029-10-01
4
Phase 1Interferon-beta
Glioblastoma Multiforme+3 more
Completed—1
N/AUnnamed
Relapsing-Remitting Multiple Sclerosis
Completed
2007-10past
1
N/AUnnamed
Relapsing-Remitting Multiple Sclerosis+1 more
Completed
2011-06-30past
1
N/AUnnamed
Multiple Sclerosis
Completed
2012-05past
1
N/AUnnamed
Crohn's Disease+3 more
Completed
2012-07past
1
N/AUnnamed
Progressive Multifocal Leukoencephalopathy
Terminated
2014-08past
1
N/AUnnamed
Multiple Sclerosis
Completed
2014-10past
1
N/AUnnamed
Multiple Sclerosis
Completed
2014-11past
1
N/AUnnamed
Multiple Sclerosis
Completed
2016-12past
1
N/AUnnamed
Frontotemporal Dementia+1 more
Completed
2019-09-23past
1
N/AUnnamed
Multiple Sclerosis (MS)
Completed
2021-10-08past
1
N/AUnnamed
Multiple Sclerosis
Terminated
2022-12-05past
1
N/AUnnamed
Healthy Volunteer
Completed
2022-12-31past
1
N/AZuranolone
Depression, Postpartum
Recruiting
2026-08-24past
1
N/ADiroximel Fumarate
Multiple Sclerosis
Active, not recruiting
2031-01-17
1
N/AUnnamed
Multiple Sclerosis
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.